Core Viewpoint - The company reported strong revenue growth in 2024, but faced a decline in net profit in Q1 2025 due to market pressures from centralized procurement and reduced surgical volumes [1][2]. Financial Performance - In 2024, the company achieved revenue of 1.41 billion yuan, a year-on-year increase of 48.24%, and a net profit of 388 million yuan, up 27.77% [1]. - For Q1 2025, revenue was 357 million yuan, reflecting a year-on-year growth of 15.07%, while net profit decreased to 93 million yuan, down 10.05% [1]. Product Performance - Revenue from artificial crystalline lenses reached 588 million yuan in 2024, growing by 17.66%, with sales volume increasing by 44.93% [2]. - The company’s revenue from myopia control products grew by 20.79%, driven by the introduction of various new products [2]. R&D Investment and New Business Growth - The company increased R&D investment to 160 million yuan in 2024, a rise of 20.80%, representing 11.33% of total revenue [3]. - The contact lens business saw significant growth, with revenue reaching 426 million yuan, a staggering increase of 211.84% [3]. Market Outlook - The company is projected to achieve revenues of 1.81 billion yuan, 2.26 billion yuan, and 2.79 billion yuan for 2025-2027, with respective growth rates of 28.44%, 24.91%, and 23.12% [4]. - Expected net profits for the same period are 467 million yuan, 600 million yuan, and 778 million yuan, with growth rates of 20.21%, 28.55%, and 29.63% [4]. Earnings Per Share - The projected EPS for the years 2025, 2026, and 2027 are 2.46 yuan, 3.17 yuan, and 4.10 yuan respectively [5].

报名：首届全球骨科大会 | 参会须知 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月22日， 爱博 医疗 发布了2024年年报。 公司2025年一季度实现收入 3.57亿 元（同比+15.07%），归母净利润0.93亿元（同比-10.05%），扣非归 母净利润0.86亿元（同比-12.83%）。 2024 年 5 月起，人工晶状体国家集采政策陆续落地实施，受此影 响，终端医院手术量减少，手术价格下降，人工晶状体出厂价格也出现下滑，这直接导致了公司2025 年第一 季度手术业务收入和毛利的增速放缓。在近视防控领域，市场竞争日益激烈，竞品不断增多，公司角膜塑形镜 出厂价格因此略有下调，对公司业绩增长的贡献也有所减弱。此外，公司的隐形眼镜业务板块尚处于培育阶 段，目前对公司利润的贡献较小，未来还有较大的待提升空间。 2024年拆分 # 关于爱博 医疗 爱博诺德（北京）医疗科技股份有限公司成立于2010年4月21日，总部位于北京中关村国家自主创新示范 区。公司是一家专注于 眼科医疗器械研发、生产和销售 的高新技术企业，于2020年在科创板上市（股票代 码：688050 ...